Aprogen’s Biosimilar Remicade To Hit Japan Next Year?
This article was originally published in PharmAsia News
Executive Summary
South Korea-based biotech firm Aprogen's biosimilar version of Remicade (Johnson & Johnson's infliximab) is set to complete a Phase III clinical study in Japan as early as this month. The company’s Japanese partner will then file for local regulatory approval immediately after completing the trial and aims to launch the product in the country in the latter half of next year.